CN1850065A - Oral use of conjugated linoleic acid and its derivatives for muscle building and skin beautification - Google Patents
Oral use of conjugated linoleic acid and its derivatives for muscle building and skin beautification Download PDFInfo
- Publication number
- CN1850065A CN1850065A CN 200510034419 CN200510034419A CN1850065A CN 1850065 A CN1850065 A CN 1850065A CN 200510034419 CN200510034419 CN 200510034419 CN 200510034419 A CN200510034419 A CN 200510034419A CN 1850065 A CN1850065 A CN 1850065A
- Authority
- CN
- China
- Prior art keywords
- cla
- linoleic acid
- skin
- conjugated linoleic
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims abstract description 120
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 120
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title claims abstract description 119
- 210000003205 muscle Anatomy 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 22
- 230000001965 increasing effect Effects 0.000 claims abstract description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 230000004060 metabolic process Effects 0.000 claims abstract description 5
- 210000001087 myotubule Anatomy 0.000 claims abstract description 5
- 230000002087 whitening effect Effects 0.000 claims abstract description 5
- 102000007469 Actins Human genes 0.000 claims abstract description 4
- 108010085238 Actins Proteins 0.000 claims abstract description 4
- 102000036675 Myoglobin Human genes 0.000 claims abstract description 4
- 108010062374 Myoglobin Proteins 0.000 claims abstract description 4
- 102000003505 Myosin Human genes 0.000 claims abstract description 4
- 108060008487 Myosin Proteins 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 210000000663 muscle cell Anatomy 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- 239000007901 soft capsule Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 15
- 241000030538 Thecla Species 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004494 ethyl ester group Chemical group 0.000 claims description 4
- 229920002527 Glycogen Polymers 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229940096919 glycogen Drugs 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 150000003751 zinc Chemical class 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 230000035790 physiological processes and functions Effects 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims 8
- 230000003064 anti-oxidating effect Effects 0.000 claims 3
- 241001122767 Theaceae Species 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 17
- 208000016261 weight loss Diseases 0.000 description 17
- 239000011575 calcium Substances 0.000 description 15
- 235000013305 food Nutrition 0.000 description 15
- 230000004580 weight loss Effects 0.000 description 15
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 12
- 241000282887 Suidae Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 235000020997 lean meat Nutrition 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229940079877 pyrogallol Drugs 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- -1 ascorbyl fatty acid esters Chemical class 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000006701 autoxidation reaction Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003307 slaughter Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037237 body shape Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000001916 dieting Nutrition 0.000 description 3
- 230000037228 dieting effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 102000012141 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000021051 daily weight gain Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000014594 pastries Nutrition 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical class N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical class C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- JGFMXQLVWUGIPI-UHFFFAOYSA-N octadeca-11,13-dienoic acid Chemical compound CCCCC=CC=CCCCCCCCCCC(O)=O JGFMXQLVWUGIPI-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000037339 smooth wrinkles Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【技术领域】【Technical field】
本发明涉及共轭亚油酸(CLA)及其衍生物口服用于增肌、健体、减肥和护肤美容的用途,本发明还涉及共轭亚油酸(CLA)及其衍生物用于动物保健的用途。本发明还涉及有关制剂的制备方法和其他组合物。The present invention relates to the use of conjugated linoleic acid (CLA) and its derivatives for oral use in muscle building, body building, weight loss and skin care and beauty. The present invention also relates to the use of conjugated linoleic acid (CLA) and its derivatives in animals Health care use. The present invention also relates to methods for the preparation of related formulations and other compositions.
【背景技术】【Background technique】
现代社会,由于科学技术的高速发展,机械化电气化、自动化、深入到人类社会的各个领域,使得人们的体力劳动消耗量大幅度降低,包括家庭主妇们每天必不可少的家务劳动,也都被现代化的设备所取代。人们日常的体力消耗量已经下降至半个世纪之前的十分之一还不到。In modern society, due to the rapid development of science and technology, mechanization, electrification, automation, and penetration into various fields of human society, people's physical labor consumption has been greatly reduced, including housewives' daily essential housework, which has also been modernized. equipment replaced. People's daily physical exertion has dropped to less than one-tenth of what it was half a century ago.
另一方面,随着饮食文化的飞速发展,各种美味食品花样繁多层出不穷,多数人已经不再为能否填饱肚子而发愁,品尝各种美味食品已经成为时尚,单位聚餐、朋友聚会、节假日改善伙食谈生意请客吃饭,探病送营养食品,各种因素促使着人们在不知不觉中吃进过量的食物。On the other hand, with the rapid development of food culture, various delicious foods emerge in endlessly. Most people no longer worry about whether they can fill their stomachs. Tasting various delicious foods has become fashionable. Improve meals, talk about business, treat guests to dinner, and send nutritious food to sick people. Various factors urge people to eat too much food without knowing it.
现代人由于体力消耗减少,又过分追加营养,造成人体能量代谢失衡,导致高粘血症、高脂血症、糖尿病、高血压、冠心病等一系列现代病。肥胖病便是这些现代病之一。二十一世纪的健康杀手——肥胖病愈来愈引起国际医学界的关注,所以有专家提出:肥胖症已和吸烟、艾滋病一起成为威胁人类健康的三大严重问题。Due to the reduction of physical exertion and excessive supplementation of nutrients in modern people, the energy metabolism of the human body is unbalanced, leading to a series of modern diseases such as hyperviscosity, hyperlipidemia, diabetes, hypertension, and coronary heart disease. Obesity is one of these modern diseases. The health killer in the 21st century—obesity has attracted more and more attention from the international medical community, so some experts pointed out that obesity has become three serious problems threatening human health together with smoking and AIDS.
近年来,减肥成为一种时尚。但是如何才能健康有效地减肥,同时又能健美?In recent years, losing weight has become a fashion. But how can you lose weight in a healthy and effective way while still looking toned?
有专家提出了一种新的减肥理念-----营养减肥!即好的减肥方法,优秀的减肥产品,才是健康减肥的唯一途径。选择好的减肥食品,通过均衡的营养,合理的膳食,达到瘦身健美的效果。营养调控减肥,一种新的理念,抛弃沉重的赘肉,重塑自我。Some experts put forward a new concept of weight loss ----- nutritional weight loss! That is, good weight loss methods and excellent weight loss products are the only way to lose weight healthily. Choose good weight loss food, through balanced nutrition, reasonable diet, to achieve the effect of weight loss and fitness. Nutritional regulation and weight loss, a new concept, discard heavy fat and reshape yourself.
“不腹泻、不节食、不乏力”是国际通行的健康减肥三原则。有些减肥药中掺有刺激代谢的药物(有的还是违禁药物,如安非那酮等),通过排泄消耗人体水分和未来得及消化吸收的食物,达到减轻人体重量的目的。其危害是引起虚脱、腹痛、恶心、呕吐、电解质紊乱、营养不良等后果,虽然也能暂时减重,但减掉的不只是脂肪,还有水、矿物质和蛋白质等重要物质,而且停药后便会反弹增肥。节食减肥的实质就是过度减少能量摄入。其危害和抑制食欲一样,能引起失眠、头晕、恶心、呕吐、营养不良、免疫功能下降。可导致神经性厌食症,重者危及生命。腹泻和节食都会造成乏力。"No diarrhea, no dieting, no fatigue" are the three internationally accepted principles of healthy weight loss. Some weight-loss drugs are mixed with drugs that stimulate metabolism (some are illegal drugs, such as bupropion, etc.), and the purpose of reducing body weight is achieved by excreting and consuming body water and food that will not be digested and absorbed in the future. The harm is that it can cause collapse, abdominal pain, nausea, vomiting, electrolyte imbalance, malnutrition and other consequences. Although it can also temporarily lose weight, it loses not only fat, but also important substances such as water, minerals and protein, and the drug is discontinued. Then it will rebound and gain weight. The essence of dieting to lose weight is to excessively reduce energy intake. Its harm is the same as that of suppressing appetite. It can cause insomnia, dizziness, nausea, vomiting, malnutrition, and decreased immune function. Can lead to anorexia nervosa, severe cases are life-threatening. Both diarrhea and dieting can cause fatigue.
因此需要寻求一种物质,这种物质能通过改善营养分配,达到减肥的目的,并且不产生失眠、头晕、恶心、呕吐、营养不良、免疫功能下降等副作用。同时,改善营养分配的协同效果是增加肌肉组织,增强肌体整体素质,实现健美的体态。Therefore, it is necessary to seek a substance that can achieve the goal of weight loss by improving nutrition distribution, and does not produce side effects such as insomnia, dizziness, nausea, vomiting, malnutrition, and decreased immune function. At the same time, the synergistic effect of improving nutrient distribution is to increase muscle tissue, enhance the overall quality of the body, and achieve a healthy body.
国外研究证明,体内共轭亚油酸可能通过减少脂肪沉积和增加脂肪细胞中脂肪的分解来降低身体脂肪。国外有学者指出,共轭亚油酸可能以两种不同的方式抑制脂肪细胞的形成,包括抑制其增殖和抑制其分化。Park等人(Park Y.et al.Effect of conjugated linoleic acid on bodycomposition in mice[J].Lipids,1997,32:853-858)的实验结果证实了,共轭亚油酸降低老鼠身体脂肪的生理学上的机理包括抑制脂肪细胞中脂肪的储存以及加快骨骼肌中的β氧化和增加骨骼肌重量。West等人发现(West D.B.Conjugated linoleic acid rapidly reduces body fat content in mice withoutaffecting energy intake[J].Am.J.Physiol.1999;276:R1172-R1179.),与不含共轭亚油酸的对照组相比,用含共轭亚油酸混合物的食物喂养的老鼠其身体脂肪的百分比下降了70%,同时身体中水分、蛋白质和灰分的百分比显著增加。Foreign studies have proved that conjugated linoleic acid in the body may reduce body fat by reducing fat deposition and increasing fat breakdown in fat cells. Foreign scholars have pointed out that CLA may inhibit the formation of adipocytes in two different ways, including inhibiting their proliferation and inhibiting their differentiation. The experimental results of Park et al. (Park Y. et al. Effect of conjugated linoleic acid on bodycomposition in mice [J]. Lipids, 1997, 32: 853-858) confirmed that conjugated linoleic acid reduces the physiology of mouse body fat The above mechanisms include inhibition of fat storage in adipocytes and acceleration of β-oxidation in skeletal muscle and increase in skeletal muscle mass. West et al found (West D.B.Conjugated linoleic acid rapidly reduces body fat content in mice withoutaffecting energy intake[J].Am.J.Physiol.1999; 276:R1172-R1179.), compared with the control without conjugated linoleic acid Rats fed a diet containing the CLA mixture had a 70 percent decrease in body fat percentage, while their body water, protein and ash percentages increased significantly compared to the control group.
Ha等人的研究发现CLA具有抗癌作用(Ha Y,et al.Inhibition of benz[a]pyrene-inducedmouse forestomach neoplasis by conjugated dienoic derivatives of linoleic acid[J].CancerRes.,1990,50:1097-1101.),并据此推断CLA为抗氧化剂,之后的CLA抗氧化性能测试表明,CLA具有强于VE的抗氧化性能。Ha et al's research found that CLA has anticancer effect (Ha Y, et al.Inhibition of benz[a]pyrene-inducedmouse forestomach neoplasis by conjugated dienoic derivatives of linoleic acid[J].CancerRes., 1990,50:1097-1101 .), and accordingly infer that CLA is an antioxidant, and the subsequent CLA antioxidant performance test shows that CLA has stronger antioxidant performance than VE.
有人把CLA同小鼠皮肤癌角质细胞共同培养,结果表明:CLA抑制TPA可以诱导产生的PEG2和AA。CLA通过调节细胞膜的磷脂成分,保护细胞膜的磷脂酶不被激活,减少花生四烯酸释放产生PEG2(Liu KL,Belury MA.Conjugated linoleic acid reduces arachidonic acidcontent and PGE2 synthesis in murine keratinocytes.Cancer letters 1998;127:15-22)。另有研究发现9z,lle-CLA能特异性结合真皮内过氧化物增殖体激活受体-α(PPAR-α),促进角质细胞的分化,抑制皮肤肿瘤的癌变(Thuillier P,et al.Activators of peroxisomeproliferator-activated receptor-αpartially inhibit mouse skin tumor promotion.Molecular Carcinogenesis 2000;29:134-142.。通过测定真皮中成纤维细胞合成的I型原胶原和与其相关联的Derorin蛋白的方式来研究CLA。将CLA和EGCG的不同组合与人体真皮中成纤维细胞共同培养,结果表明,CLA和EGCG单独使用均能提高I型原胶原的含量,并且两者的联合使用具有协同作用。而I型原胶原和与其相关联的Derorin蛋白含量的提高可以平滑皱纹,修复光损伤性皮肤,表现出抗衰老的作用。CLA具有清除自由基和抗脂质过氧化作用(WO0182861 Treatment of skin damage using conjugated linoleic acid and ascorbyl fattyacid esters),促进皮肤胶原细胞生长,维持细胞的增殖周期,防止细胞朝衰老、分化方向发展,从而发挥抗衰老,抗炎作用。Someone co-cultured CLA with mouse skin cancer keratinocytes, and the results showed that: CLA can inhibit the production of PEG2 and AA that can be induced by TPA. CLA regulates the phospholipid composition of the cell membrane, protects the phospholipase of the cell membrane from being activated, and reduces the release of arachidonic acid to produce PEG2 (Liu KL, Belury MA. Conjugated linoleic acid reduces arachidonic acid content and PGE 2 synthesis in murine keratinocytes. Cancer letters 1998; 127:15-22). Another study found that 9z, lle-CLA can specifically bind to peroxisome proliferator-activated receptor-α (PPAR-α) in the dermis, promote the differentiation of keratinocytes, and inhibit the carcinogenesis of skin tumors (Thuillier P, et al. Activators of peroxisome proliferator-activated receptor-α partially inhibit mouse skin tumor promotion. Molecular Carcinogenesis 2000;29:134-142. CLA was studied by measuring the synthesis of type I procollagen and its associated Derorin protein by fibroblasts in the dermis. Different combinations of CLA and EGCG were co-cultured with fibroblasts in human dermis. The results showed that both CLA and EGCG alone could increase the content of type I procollagen, and the combined use of the two had a synergistic effect. While type I procollagen The improvement of the Derorin protein content associated with it can smooth wrinkles, repair photodamaged skin, and show anti-aging effects. CLA has scavenging free radicals and anti-lipid peroxidation (WO0182861 Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters), promote the growth of skin collagen cells, maintain the proliferation cycle of cells, prevent cells from developing in the direction of aging and differentiation, thereby exerting anti-aging and anti-inflammatory effects.
在US6551602;US2004043963;US6403064;WO0182861专利中公开了CLA在局部用组合物和皮肤美容保健中的用途,如抗皱纹,增强皮肤弹性和厚度,修复光损伤性皮肤,美白作用,以及保湿,营养,抗炎和抗过敏等。在US6300374中公开了共轭亚油酸的锌盐可治疗多种皮肤病,如湿疹、牛皮、皮炎等。这些研究或已公开的专利表明CLA外用可以营养或护理裸露皮肤,我们假设口服的CLA也可以达到皮肤部位发挥同样药理作用。US6551602; US2004043963; US6403064; WO0182861 patents disclose the use of CLA in topical compositions and skin beauty care, such as anti-wrinkle, enhancing skin elasticity and thickness, repairing photodamaged skin, whitening effect, and moisturizing, nutrition, Anti-inflammatory and anti-allergic etc. It is disclosed in US6300374 that the zinc salt of conjugated linoleic acid can treat various skin diseases, such as eczema, psoriasis, dermatitis and the like. These studies or published patents suggest that topical CLA can nourish or care for bare skin, and we hypothesize that oral CLA can also reach the skin site to exert the same pharmacological effects.
基于上述考虑,本申请人通过实验意外惊人地发现口服共轭亚油酸(CLA)及其衍生物能改善营养分配、减肥增肌、增强免疫能力,同时还具有皮肤营养与美容的作用。Based on the above considerations, the applicant unexpectedly discovered through experiments that oral administration of conjugated linoleic acid (CLA) and its derivatives can improve nutrition distribution, lose weight and increase muscle, enhance immunity, and also have skin nutrition and beauty effects.
【发明内容】【Content of invention】
本发明的目的是将共轭亚油酸(CLA)及其衍生物口服用于增肌、健体、减肥、皮肤营养与护肤美容的用途,尤其用于增肌健体(健美)的用途。本发明还涉及共轭亚油酸(CLA)及其衍生物用于动物保健的用途。本发明还涉及有关制剂的制备方法和其他组合物。The object of the present invention is to orally administer conjugated linoleic acid (CLA) and its derivatives for muscle building, fitness, weight loss, skin nutrition and skin care, especially for muscle building (bodybuilding). The invention also relates to the use of conjugated linoleic acid (CLA) and its derivatives for animal health. The present invention also relates to methods for the preparation of related formulations and other compositions.
实际上,本发明涉及共轭亚油酸(CLA)及其衍生物在制备用于增肌健体和护肤营养、美容用途的口服制剂的应用;In fact, the present invention relates to the application of conjugated linoleic acid (CLA) and its derivatives in the preparation of oral preparations for muscle building, skin care, nutrition and cosmetic purposes;
如上所述的应用,共轭亚油酸(CLA)及其衍生物口服进入皮肤与肌肉组织,促进其新陈代谢,清除或置换黑色素,达到美白嫩肤之效;或增加肌糖原、肌球蛋白、肌动蛋白和肌红蛋白的含量,促进肌肉细胞生成,达到增加肌肉体积和肌纤维强度的功效;As mentioned above, conjugated linoleic acid (CLA) and its derivatives orally enter the skin and muscle tissue to promote their metabolism, remove or replace melanin, and achieve the effect of whitening and skin rejuvenation; or increase muscle glycogen, myosin , the content of actin and myoglobin, promote the generation of muscle cells, and achieve the effect of increasing muscle volume and muscle fiber strength;
如上所述的制剂,其制剂包括片剂、软胶囊、冲剂、颗粒剂、胶囊剂和丸剂;As above-mentioned preparation, its preparation comprises tablet, soft capsule, electuary, granule, capsule and pill;
如上所述的制剂,制剂含有任选的一种或多种常用的具抗氧化生理活性物质;The above-mentioned preparation, the preparation contains optional one or more commonly used antioxidant physiologically active substances;
如上所述的CLA及其衍生物,其中CLA包含一种或多种9,11-10,12-和11,13-十八碳二烯酸的顺式和反式形式异构体;CLA衍生物为CLA的乙酯、甘油三酯,钙盐、锌盐以及其他可能的衍生物或盐;CLA and derivatives thereof as described above, wherein CLA comprises one or more cis and trans form isomers of 9,11-10,12- and 11,13-octadecadienoic acid; CLA derived The substance is ethyl ester, triglyceride, calcium salt, zinc salt and other possible derivatives or salts of CLA;
如上所述的CLA及其衍生物,其特征在于共轭亚油酸(CLA)及其衍生物的用量为0.01-20%(W/W);The above CLA and its derivatives, characterized in that the amount of conjugated linoleic acid (CLA) and its derivatives is 0.01-20% (W/W);
如上所述的制剂,常用的具抗氧化生理活性物质为维生素E或TBHQ或茶多酚或硒(Se);As mentioned above, the commonly used antioxidant physiologically active substances are vitamin E or TBHQ or tea polyphenols or selenium (Se);
如上所述的制剂,常用的具抗氧化生理活性物质,除了保护CLA及其衍生物发挥正常生理功能外,还起着协同清除体内自由基的作用,特别针对肌肉增加,肌体活动增强后产生更多的自由基状况,达到清洁肌体内环境的功效。As mentioned above, the commonly used antioxidant physiologically active substances, in addition to protecting CLA and its derivatives to exert normal physiological functions, also play a role in synergistic scavenging of free radicals in the body, especially for muscle growth and more active substances after body activity is enhanced. There are many free radicals, so as to achieve the effect of cleaning the internal environment of the human body.
本发明采用了细胞实验和动物实验来研究共轭亚油酸(CLA)及其衍生物减脂增肌,健美体态和营养皮肤的作用。The invention adopts cell experiments and animal experiments to study the effects of conjugated linoleic acid (CLA) and its derivatives on reducing fat and increasing muscle, building body and nourishing skin.
细胞实验采用小鼠3T3-L1脂肪前体细胞。3T3-L1细胞株是小鼠胚胎来源、具有纤维母细胞形态的前脂肪细胞,是目前国际上公认的研究成脂过程的细胞株。在分化诱导刺激下,3T3-L1前体脂肪细胞分化为成熟的脂肪细胞。本研究利用脂肪前体细胞体外培养实验,脂肪前体细胞在加入分化诱导剂的培养液中培养分化。实验设2个试验组,对照组和CLA组。对照组培养液中不加入其他物质培养;CLA组则在培养液中加入CLA(浓度呈梯度变化),培养至第八天时进行形态学观察,与对照组来比较。The cell experiments used mouse 3T3-L1 preadipocytes. The 3T3-L1 cell line is a preadipocyte derived from mouse embryos and has a fibroblast morphology. It is currently an internationally recognized cell line for studying the process of adipogenicity. Under differentiation-inducing stimuli, 3T3-L1 preadipocytes differentiate into mature adipocytes. In this study, the in vitro culture experiment of adipocytes was used, and adipocytes were cultured and differentiated in the culture medium added with differentiation inducers. The experiment consisted of two test groups, the control group and the CLA group. The culture medium of the control group was cultured without adding other substances; the culture medium of the CLA group was cultured with CLA (concentration changed in a gradient), and the morphology was observed on the eighth day, and compared with the control group.
结果:比较对照组,CLA组的细胞明显多呈纤维状,散见细小油滴,表明对3T3-L1脂肪前体细胞的增殖以及向脂肪细胞的分化有一定抑制作用,提示共轭亚油酸(CLA)具有潜在的减肥、降脂作用。Results: Compared with the control group, the cells in the CLA group were obviously fibrous, and small oil droplets were scattered, indicating that it had a certain inhibitory effect on the proliferation of 3T3-L1 adipose precursor cells and the differentiation into adipocytes, suggesting that conjugated linoleic acid (CLA) has potential weight loss and lipid-lowering effects.
动物实验主要研究了共轭亚油酸(CLA)及其衍生物改善肌体肌肉组成和促进营养物质再分配,实现结实肌肉和肌体肌肉分布均匀的减肥健美的作用,同时还研究了实验动物的皮肤状态。CLA组试验动物明显优于对照组:皮肤光泽度好,较少出现因皮肤疾病所致的不正常斑点或肤色。共轭亚油酸(CLA)及其衍生物这些优点,是目前市场上热销的减肥产品所无法比拟的。Animal experiments mainly studied the effects of conjugated linoleic acid (CLA) and its derivatives on improving body muscle composition and promoting the redistribution of nutrients to achieve weight loss and bodybuilding with firm muscles and uniform distribution of body muscles. At the same time, the skin of experimental animals was also studied. state. The test animals in the CLA group were significantly better than the control group: the skin gloss was better, and there were fewer abnormal spots or skin colors caused by skin diseases. These advantages of conjugated linoleic acid (CLA) and its derivatives are unmatched by the hot-selling slimming products on the market.
实验设2个试验组:空白对照组与共轭亚油酸钙(共轭亚油酸钙为共轭亚油酸钙盐的存在形式,简称:CLA-Ca)组,每个试验组均设2个重复组,每个重复组设5头猪,共20头试验猪(2♀,3♂/重复)。试验猪在试验前均测定体重,确保每个重复组间试验猪体重、体型差异检验不显著。预试期5天,正式试验期64天。There were 2 test groups in the experiment: blank control group and conjugated linoleic acid calcium (conjugated linoleic acid calcium is the form of conjugated linoleic acid calcium salt, referred to as: CLA-Ca) group, each test group was set 2 There were 2 repetition groups, 5 pigs in each repetition group, a total of 20 test pigs (2♀, 3♂/replication). The body weight of the test pigs was measured before the test to ensure that the test pigs' body weight and body shape were not significantly different among each repeated group. The pre-test period is 5 days, and the formal test period is 64 days.
CLA-Ca粉按6.7‰的剂量(折合纯CLA-Ca 5.0‰)直接添加到对应试验组猪的粉状饲料中,搅拌均匀,每天连续饲喂。The dose of CLA-Ca powder was 6.7‰ (equivalent to pure CLA-Ca 5.0‰) directly into the powdered feed of pigs in the corresponding test group, stirred evenly, and fed continuously every day.
生产性能指标测定:实验阶段始末记录的猪个体称重,记录每重复组的采食量、计算平均日增重、料肉比、日采食量。Determination of production performance indicators: Weigh the individual pigs recorded at the beginning and end of the experimental stage, record the feed intake of each repeated group, and calculate the average daily gain, feed-to-meat ratio, and daily feed intake.
活体测膘分级采用B超仪分别于实验阶段的始末在动物试验现场进行活体测膘分级,检测项目包括B超测量背膘厚、眼肌面积,估算胴体瘦肉率。In vivo fat measurement and grading adopt B-ultrasound instrument to carry out in-vivo fat measurement and grading at the animal test site at the beginning and end of the experimental stage. The testing items include B-ultrasound measurement of backfat thickness, eye muscle area, and estimation of carcass lean meat percentage.
试验结束后,空白组、CLA-Ca组每栏挑选体型中等猪各2头(♀,♂各1头),共8头,空腹24h后屠宰,按GB8467-87《瘦肉型猪性能测定技术规程》方法进行,测定眼肌面积、背膘厚、肌间脂肪、计算胴体瘦肉率。分割左侧胴体瘦肉、脂肪、皮、骨称重;测定屠宰后45分钟在第13~14肋间测背最长肌的pH值,进行肉色和大理石纹级别评定。实验结果见表1-3:结果详见表1-3:After the test, 2 medium-sized pigs (1 each for ♀ and 1 ♂) were selected from each column of the blank group and the CLA-Ca group, a total of 8 pigs were slaughtered after 24 hours of fasting. "Procedures" method, measuring eye muscle area, backfat thickness, intermuscular fat, and calculating carcass lean meat percentage. Divide the lean meat, fat, skin, and bone of the left carcass and weigh them; measure the pH value of the longissimus dorsi muscle at the 13th to 14th intercostal space 45 minutes after slaughter, and evaluate the meat color and marbling grade. The experimental results are shown in Table 1-3: the results are detailed in Table 1-3:
表1 CLA钙对肥育猪增重效果及饲料转化效率的影响
表2 CLA钙对屠体性状的影响
表3 CLA钙对胴体性状的影响
以上实验表明:The above experiments show that:
(1)皮肤状态和肉品质评价:试验组皮肤白净红润,被毛整洁发亮,较少出现因皮肤疾病造成的红疹、斑块等异常皮肤现象,显示出CLA对皮肤状态的改进功能;肉品质评价方面,试验组的肉色评分比对照组提高了。(1) Evaluation of skin condition and meat quality: the skin of the test group was fair and ruddy, the coat was neat and shiny, and there were less abnormal skin phenomena such as rashes and plaques caused by skin diseases, showing the improvement function of CLA on skin condition; In terms of meat quality evaluation, the meat color score of the experimental group was higher than that of the control group.
(2)身体整体体型和肌肉状态评价:体型上,试验组育肥猪身型长,背平直,腹部肌肉结实收缩,臀部肌肉浑圆结实且分布均匀,活动状态强。屠宰分割后可见,试验组育肥猪肌纤维的增粗和纵裂增殖使肌肉的体积增大、重量增加,其表现为肌肉形态得到了改变,故身体整体体型得到良性发展。(2) Evaluation of overall body shape and muscle state: In terms of body shape, the fattening pigs in the test group were long in body, straight in back, firm and contracted in abdominal muscles, round and firm in hip muscles and evenly distributed, and in a strong state of activity. After slaughtering and dividing, it can be seen that the thickening of muscle fibers and the proliferation of longitudinal fissures in the fattening pigs in the test group increased the volume and weight of the muscles, which manifested as changes in the shape of the muscles, so the overall shape of the body was benignly developed.
(3)对增重效果及饲料转化效率的影响:与对照组比较,试验组的日增重,平均日采食量和料重比都降低了。(3) Effects on weight gain and feed conversion efficiency: Compared with the control group, the daily weight gain, average daily feed intake and feed-to-weight ratio of the experimental group were all reduced.
(4)屠宰率、胴体性状:试验组的后腿比例、胴体瘦肉率、胴体眼肌面积和B超眼肌面积提高了,平均膘厚、B超膘厚和皮脂相对重比对照组下降了。试验组的瘦肉率显著高于对照组。(4) Slaughter rate and carcass traits: the proportion of hind legs, carcass lean meat percentage, carcass eye muscle area and B-ultrasound eye muscle area in the experimental group increased, and the average fat thickness, B-ultrasonic fat thickness and relative sebum weight decreased compared with the control group up. The lean meat percentage of the test group was significantly higher than that of the control group.
人呼吸氧气进入体内,有一部份转化为活性自由基,会导致细胞衰老,皱纹增多,记忆力减退,削弱免疫系统。因此,摄入抗氧化剂能有效清除活性自由基,延缓机体和皮肤衰老。When people breathe oxygen into the body, some of it is transformed into active free radicals, which will cause cell aging, increase wrinkles, memory loss, and weaken the immune system. Therefore, the intake of antioxidants can effectively scavenge active free radicals and delay the aging of the body and skin.
本发明采用了连苯三酚自氧化法研究共轭亚油酸(CLA)及其衍生物的抗氧化作用。The invention adopts a pyrogallol autoxidation method to study the antioxidant effect of conjugated linoleic acid (CLA) and its derivatives.
将连苯三酚用稀盐酸配成6mmol/L的溶液。将0.02%的样品加入到4.1mL的pH8.2缓冲液中,混合均匀。取0.1mL的连苯三酚液加到上述混合液中,在紫外分光光度仪上采用时间程序在320nm处连续测量300s,连苯三酚自氧化速率用每分钟其自氧化产物在波长320nm处的吸光度增加量 表示。样品对连苯三酚自氧化速率的百分抑制率由式(1-1)计算。Make a 6mmol/L solution of pyrogallol with dilute hydrochloric acid. Add 0.02% of the sample to 4.1 mL of pH 8.2 buffer and mix well. Take 0.1mL of pyrogallol solution and add it to the above mixed solution, and use the time program on the ultraviolet spectrophotometer to measure continuously at 320nm for 300s. The increase in absorbance express. The percentage inhibition rate of the sample pyrogallol autoxidation rate was calculated by formula (1-1).
结果见表4。The results are shown in Table 4.
式中, 为对照组连苯三酚自氧化速率; 为加入样品时的连苯三酚自氧化速率。实验结果见表4:In the formula, is the autoxidation rate of pyrogallol in the control group; is the autoxidation rate of pyrogallol when adding the sample. The experimental results are shown in Table 4:
表4 CLA及其乙酯对超氧阴离子的抑制率
上述结果表明在连苯三酚自氧化体系试验中,相同浓度下本发明的CLA和CLA乙酯具有比维生素E更强的清除超氧阴离子的作用,是一种有效的抗氧化剂。The above results show that in the pyrogallol autoxidation system test, CLA and CLA ethyl ester of the present invention have a stronger superoxide anion scavenging effect than vitamin E at the same concentration, and are an effective antioxidant.
本发明所述的共轭亚油酸(CLA)及其衍生物口服用于减肥增肌和护肤美容的用途,将30例肥胖病人(自愿者)随机分为两组,一组分天服用4.5gCLA,另一组只服不含任何成分的安慰剂。试食3个月后,测定发现,受试者在食用CLA后,腰围、腹围、臀围显著减小,尤以腰围、腹围更明显,人体皮下脂肪厚度也明显减少。统计结果表明,安慰组体重下降率为0%;共轭亚油酸组体重下降率为100%,平均体重下降了12.5%,同时体脂比例显著减少,肌肉比例明显增加,说明受试产品具有减肥与增加肌肉的作用。Conjugated linoleic acid (CLA) and derivatives thereof described in the present invention are used orally for weight loss, muscle gain and skin care and cosmetic purposes. 30 obese patients (volunteers) were randomly divided into two groups, and one group took 4.5 gCLA, and the other group received only a placebo containing nothing. After 3 months of food testing, it was found that after eating CLA, the subjects' waist circumference, abdominal circumference, and hip circumference decreased significantly, especially the waist circumference and abdominal circumference, and the thickness of subcutaneous fat in the human body also decreased significantly. The statistical results show that the weight loss rate of the placebo group is 0%; the body weight loss rate of the CLA group is 100%, with an average weight loss of 12.5%. Lose weight and increase muscle.
本发明与现有产品相比具有如下的优点:共轭亚油酸(CLA)及其衍生物口服进入皮肤与肌肉组织,促进其新陈代谢,清除或置换黑色素,达到美白嫩肤之效;或增加肌糖原、肌球蛋白、肌动蛋白和肌红蛋白的含量,促进肌肉细胞生成,达到增加肌肉体积和肌纤维强度的功效。Compared with the existing products, the present invention has the following advantages: Conjugated linoleic acid (CLA) and its derivatives are taken orally into the skin and muscle tissue to promote their metabolism, remove or replace melanin, and achieve the effect of whitening and skin rejuvenation; The content of muscle glycogen, myosin, actin and myoglobin can promote the production of muscle cells and achieve the effect of increasing muscle volume and muscle fiber strength.
【具体实施方式】【Detailed ways】
下面将描述本发明的几个具体实施方式,但本发明的内容完全不局限于此。Several specific embodiments of the present invention will be described below, but the content of the present invention is not limited thereto.
实施例1:CLA功能调和油Example 1: CLA functional blend oil
(1)取5gCLA与芝麻油、橄榄油或葵花子油混合均匀,配成100g调和油,分装后得成品。食用方式:直接作为食用油加入沙拉或其他生、熟食品的调味佐品中。(1) Mix 5g of CLA with sesame oil, olive oil or sunflower oil evenly to make 100g of blended oil, and obtain the finished product after packaging. Ways of eating: Add directly as cooking oil to salads or other seasonings for raw and cooked foods.
实施例2:含共轭亚油酸及其衍生物的功能型食品Example 2: Functional food containing conjugated linoleic acid and its derivatives
(1)CLA巧克力:取1gCLA与可可浆、可可粉、可可脂、奶粉、食用油脂、砂糖、乳化剂及香料按一定比例混合均匀得100g,用旋转磨辊使其微粒化,并用精磨机精磨后,再用旋转磨辊加工成粉末细片状,过60目的筛,最后用成型机压榨机成型。(1) CLA chocolate: Mix 1g of CLA with cocoa pulp, cocoa powder, cocoa butter, milk powder, edible oil, sugar, emulsifier and spices in a certain proportion to obtain 100g, use a rotating grinding roller to make it micronized, and use a fine grinder After fine grinding, it is processed into fine powder flakes with a rotating grinding roller, passed through a 60-mesh sieve, and finally shaped by a molding machine press.
(2)CLA-Ca糖果:将白砂糖放入铝锅中,加水少许,煎熬至挑起即成丝状而不粘时,将温度降至40℃,加入5g CLA钙粉,配成100g,熄火。将糖倒在表面涂过食用油的搪瓷盘中,待稍冷,用刀将糖割成小块即可。(2) CLA-Ca candy: Put white granulated sugar in an aluminum pot, add a little water, and cook until it becomes silky and not sticky, then lower the temperature to 40°C, add 5g of CLA calcium powder, and make 100g. turn off the flame. Pour the sugar into an enamel plate coated with edible oil, wait for it to cool slightly, and cut the sugar into small pieces with a knife.
(3)制备含CLA的西点糖粉:取10gCLA与西点糖粉混合得100g,搅拌,研碎,过60目筛,分装,即得成品。(3) Preparation of pastry sugar powder containing CLA: Mix 10 g of CLA and pastry sugar powder to obtain 100 g, stir, grind, pass through a 60-mesh sieve, and pack separately to obtain the finished product.
实施例3:含共轭亚油酸及其衍生物的营养补品Example 3: Nutritional supplements containing conjugated linoleic acid and its derivatives
(1)含CLA-Ca的合剂:取3gCLA-Ca粉与蔗糖、肌苷、儿茶酚、苯甲酸钠按一定比例混合,用100mL蒸馏水溶解,充分搅拌,使之完全溶解。分装于易拉罐中,即得。服用方法:加入牛奶或其他运动型饮料和食品中食用。(1) Mixture containing CLA-Ca: Mix 3g of CLA-Ca powder with sucrose, inosine, catechol, and sodium benzoate in a certain proportion, dissolve in 100mL of distilled water, stir well to make it completely dissolved. Packed in cans, that is. Directions for use: Add to milk or other sports drinks and food.
(2)制备含CLA的泡腾片:取5gCLA和枸橼酸、富马酸、碳酸氢钠按一定比例混合均匀,用乙醇制成软材,过60目筛,制粒,所得颗粒于60℃干燥,整粒,加入低取代羟丙基纤维素,硬脂酸镁充分混合均匀得100g,以12mm浅凹冲压片,即得。服用方法:加入牛奶或其他运动型饮料和食品中食用。(2) Preparation of effervescent tablets containing CLA: get 5g of CLA and mix them uniformly with citric acid, fumaric acid, and sodium bicarbonate in a certain proportion, make a soft material with ethanol, pass through a 60-mesh sieve, and granulate. Dry at ℃, granulate, add low-substituted hydroxypropyl cellulose and magnesium stearate, mix thoroughly to obtain 100g, punch out tablets with 12mm dimples, and obtain. Directions for use: Add to milk or other sports drinks and food.
实施例4:含共轭亚油酸及其衍生物的保健品和药品原料Example 4: Health care products and pharmaceutical raw materials containing conjugated linoleic acid and its derivatives
(1)制备含CLA钙盐的硬胶囊剂:取5gCLA钙盐,与维生素E、蔗糖、淀粉按一定比例混合配成100g,粉碎后,过100目筛,装入硬胶囊,即得。(1) Preparation of hard capsules containing CLA calcium salt: get 5g of CLA calcium salt, mix it with vitamin E, sucrose, and starch in a certain proportion to make 100g, after crushing, pass through a 100-mesh sieve, and pack into hard capsules.
(2)制备含CLA的软胶囊剂:将明胶、甘油、蒸馏水按40∶12∶48的比例混合配成胶液,将胶液和CLA分别通过滴丸机双孔,按不同速度滴出,在冷却的液体石蜡中进行凝固,三者的用量比例为1.12∶0.9∶0.86。所得的胶丸于20℃左右干燥,即得。服用方法:口服,温开水或牛奶送服。(2) Preparation of CLA-containing soft capsules: gelatin, glycerin, and distilled water are mixed in a ratio of 40:12:48 to form a glue solution, and the glue solution and CLA are passed through the double holes of the dropping pill machine and dripped out at different speeds. Solidify in the cooled liquid paraffin, the dosage ratio of the three is 1.12:0.9:0.86. The obtained capsules are dried at about 20°C to obtain. Dosage: Take orally, take with warm water or milk.
(3)共轭亚油酸微囊剂:取3gCLA与乙基纤维素,淀粉,滑石粉,硬脂酸甘油,维生素E等按一定比例溶于100ml乙醇中,混合均匀,于喷雾干燥机中喷雾干燥,即得。使用方法:作为药物和食品生产原料用。(3) Conjugated linoleic acid microcapsules: Dissolve 3g of CLA, ethyl cellulose, starch, talcum powder, glycerin stearate, vitamin E, etc. in 100ml of ethanol in a certain proportion, mix well, and place in a spray dryer Spray drying, that is. Usage: used as raw material for medicine and food production.
(4)制备含CLA的口腔速溶片:取5gCLA与多糖、明胶、多肽,滑石粉,乙醇、着色剂等按一定比例配成混悬液,定量分装于一定模具中,冷冻成固态,再减压升温,通过升华作用除去水分,得到高孔隙率的固体制剂100g。服用方法:不需水送服,在口内遇到唾液迅速溶解。(4) Prepare the oral instant tablet containing CLA: get 5g CLA and polysaccharide, gelatin, polypeptide, talcum powder, ethanol, coloring agent etc. are made into suspension in certain proportion, quantitatively subpackage in certain mould, freeze into solid state, then The temperature was raised under reduced pressure, and water was removed by sublimation to obtain 100 g of a high-porosity solid preparation. How to take: Take it without water, it dissolves quickly when it encounters saliva in the mouth.
(5)制备含CLA的口含片:将乳糖、糖粉、17%淀粉浆按一定比例混合均匀,过60目筛,湿颗粒放干燥箱内干燥(60℃-80℃),得空白颗粒。取5gCLA与空白颗粒混合得100g,用压片机压制成片,即得。服用方法:舌下含服。(5) Preparation of buccal tablets containing CLA: mix lactose, sugar powder, and 17% starch slurry evenly in a certain proportion, pass through a 60-mesh sieve, and dry the wet granules in a drying oven (60°C-80°C) to obtain blank granules . Take 5g of CLA and mix it with blank granules to obtain 100g, and press it into tablets with a tablet machine. How to take: Take it sublingually.
(6)制备含CLA的微囊:将乙基纤维素(EC)溶于丙酮中,再加入2gCLA和0.7g滑石粉,搅拌,所得混悬液加入到含有司盘的液体石蜡中,将体系温度逐渐升至35℃,保温搅拌,升温至57℃,搅拌,减压抽滤,所得固体物用正己烷洗涤3次,抽干,干燥,制得100g微囊。(6) Preparation of CLA-containing microcapsules: dissolve ethyl cellulose (EC) in acetone, add 2 g of CLA and 0.7 g of talc, stir, and add the resulting suspension to liquid paraffin containing Span, and the system The temperature was gradually raised to 35°C, kept stirring, then raised to 57°C, stirred, filtered under reduced pressure, the obtained solid was washed 3 times with n-hexane, drained and dried to obtain 100 g of microcapsules.
(7)制备含CLA乙酯的营养液:取2gCLA乙酯与蜂蜜、蔗糖酯、维生素E、硒、蛋白糖、脱氢乙酸钠按一定比例混合,加水至100ml,搅拌均匀,均质,然后装瓶、封口、灭菌后,得成品。(7) Preparation of nutrient solution containing CLA ethyl ester: mix 2g of CLA ethyl ester with honey, sucrose ester, vitamin E, selenium, protein sugar, and sodium dehydroacetate in a certain proportion, add water to 100ml, stir evenly, and then After bottling, sealing, and sterilization, the finished product is obtained.
实施例5:含有共轭亚油酸及其衍生物动物食粮和饲料Example 5: Animal Food and Feed Containing Conjugated Linoleic Acid and Its Derivatives
(1)直接添加入动物食粮和饲料:取5gCLA钙粉与95g狗粮或猪饲料混合,搅拌均匀,即得。(1) Add directly to animal food and feed: Mix 5g of CLA calcium powder with 95g of dog food or pig feed, and stir evenly.
(2)生产宠物食粮的原料添加剂:取0.05gCLA与鸡胸肉、山梨糖醇、红曲米素、维生素E、山梨酸钾、糖精钠、亚硝酸钠按一定比例混合配成100g,将混合物控水去油、冷冻切片、烘干、包装,即得。(2) Raw material additives for the production of pet food: take 0.05g of CLA and mix it with chicken breast meat, sorbitol, red yeast rice, vitamin E, potassium sorbate, sodium saccharin, and sodium nitrite in a certain proportion to form 100g, and control the mixture Degreasing with water, freezing and slicing, drying, packing, and it is ready.
(3)生产动物饲料的原料添加剂:将玉米、豆粕、麸皮,剔除杂质,90℃烘18h,按10∶3∶2的比例进行粗混合,用球蘑机粉碎并通过80目筛,取筛粉95g与5gCLA钙粉混合均匀,分装于洗净棕色瓶中,充氮气,封口后,用1.5兆拉德的剂量进行同位素钴60照射,以便长期保存。(3) Raw material additives for the production of animal feed: remove impurities from corn, soybean meal, and bran, bake at 90°C for 18 hours, roughly mix them in a ratio of 10:3:2, crush them with a ball mushroom machine and pass through an 80-mesh sieve, and take Mix 95g of sieved powder with 5g of CLA calcium powder evenly, pack them into clean brown bottles, fill them with nitrogen gas, seal them, and irradiate them with the isotope cobalt 60 at a dose of 1.5 Mrad for long-term storage.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510034419 CN1850065A (en) | 2005-04-23 | 2005-04-23 | Oral use of conjugated linoleic acid and its derivatives for muscle building and skin beautification |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510034419 CN1850065A (en) | 2005-04-23 | 2005-04-23 | Oral use of conjugated linoleic acid and its derivatives for muscle building and skin beautification |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101486144A Division CN101129352A (en) | 2005-04-23 | 2005-04-23 | Use of oral calcium conjugate linoleate for skin beauty |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1850065A true CN1850065A (en) | 2006-10-25 |
Family
ID=37131577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510034419 Pending CN1850065A (en) | 2005-04-23 | 2005-04-23 | Oral use of conjugated linoleic acid and its derivatives for muscle building and skin beautification |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1850065A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101945653A (en) * | 2008-01-02 | 2011-01-12 | 海洋生物有限公司 | Compositions and methods for treating neurodegenerative diseases |
CN103385516A (en) * | 2013-07-29 | 2013-11-13 | 安徽燕之坊食品有限公司 | Liquid supplement |
CN112546195A (en) * | 2020-12-16 | 2021-03-26 | 刘袭文 | Safflower polypeptide light tablet |
CN112674208A (en) * | 2020-12-30 | 2021-04-20 | 华南农业大学 | Application of trans-10 cis-12 conjugated linoleic acid in enhancing skeletal muscle exercise endurance |
CN114097938A (en) * | 2021-10-27 | 2022-03-01 | 浙江大学 | Feed for promoting muscle injury repair of mice and application |
WO2022087684A1 (en) * | 2020-10-30 | 2022-05-05 | Animal Control Technologies (Australia) Pty Ltd | Hygroscopic salt microencapsulation, and uses thereof |
-
2005
- 2005-04-23 CN CN 200510034419 patent/CN1850065A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101945653A (en) * | 2008-01-02 | 2011-01-12 | 海洋生物有限公司 | Compositions and methods for treating neurodegenerative diseases |
CN103385516A (en) * | 2013-07-29 | 2013-11-13 | 安徽燕之坊食品有限公司 | Liquid supplement |
WO2022087684A1 (en) * | 2020-10-30 | 2022-05-05 | Animal Control Technologies (Australia) Pty Ltd | Hygroscopic salt microencapsulation, and uses thereof |
EP4236692A4 (en) * | 2020-10-30 | 2024-10-16 | Animal Control Technologies (Australia) Pty Ltd | Hygroscopic salt microencapsulation, and uses thereof |
CN112546195A (en) * | 2020-12-16 | 2021-03-26 | 刘袭文 | Safflower polypeptide light tablet |
CN112674208A (en) * | 2020-12-30 | 2021-04-20 | 华南农业大学 | Application of trans-10 cis-12 conjugated linoleic acid in enhancing skeletal muscle exercise endurance |
CN114097938A (en) * | 2021-10-27 | 2022-03-01 | 浙江大学 | Feed for promoting muscle injury repair of mice and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108618129A (en) | Sarcopenia tailored version clinical nutrition formula and preparation method thereof | |
JP6205616B2 (en) | Beautiful skin promoter and its use | |
JP5102434B2 (en) | Orally administrable composition for improving skin quality | |
JPWO2006093267A1 (en) | Fermentation composition having immunomodulatory action | |
JP5685752B2 (en) | Blood flow promoting agent | |
CN103493983B (en) | Feed additive for improving fur quality of fur-bearing animal and manufacturing method thereof | |
JP2008074816A (en) | In vivo antioxidant | |
KR102525595B1 (en) | Health food composition containing fish collagen | |
CN104543379A (en) | Plant extract contained pet feed with health care function and preparation method of pet feed | |
JP2025003735A (en) | Oral Compositions | |
JP5597828B2 (en) | Hair restorer | |
CN1850065A (en) | Oral use of conjugated linoleic acid and its derivatives for muscle building and skin beautification | |
JP2012067082A (en) | Oral composition | |
CN1271187C (en) | Perilla oil and its preparation process and use | |
TW202421177A (en) | Composition for ameliorating fatigue, sleep disturbance or eye fatigue and menopausal symptoms | |
KR101757841B1 (en) | Composition for inhibiting obesity comprising complex salt of baicalin and zinc | |
KR20180133271A (en) | Preparations using herbal medicine extracts and powders and their manufacturing methods | |
CN107006699A (en) | A kind of meat sheep feed containing Chinese herbal medicine | |
JP6024942B2 (en) | Testosterone secretion promoter, anti-fatigue agent, and production method and use thereof | |
CN101129352A (en) | Use of oral calcium conjugate linoleate for skin beauty | |
EP4044824A1 (en) | Nutritional supplement | |
KR20140070687A (en) | Composition for obesity treatment and improvement which contains extract of tribulus terrestris | |
CN108271942A (en) | A kind of pigeon feed and preparation method thereof | |
JP7131785B1 (en) | Skin moisturizing agent and skin barrier function improving agent | |
JP7421184B2 (en) | Agents for increasing and/or maintaining skin moisture content and skin oil content |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20061025 |